Stockreport

Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3

Windtree Therapeutics, Inc.  (WINT) 
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: windtreetx.investorroom.com
PDF After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the in [Read more]